Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Nomenclature01:17

Drug Nomenclature

During the development of a new pharmaceutical, the manufacturer initially assigns a code name to the drug. Once approved, the drug receives a United States Adopted Name (USAN)—a generic, nonproprietary designation. Upon being listed in the United States Pharmacopeia, this nonproprietary name becomes the drug's official name. Additionally, the manufacturer assigns a proprietary name or trademark, which serves as the brand name under which the drug is marketed. It is worth noting that the same...
Clinically Relevant Drug Product Specifications: Methods of Establishment01:29

Clinically Relevant Drug Product Specifications: Methods of Establishment

Product specifications define the acceptable quality of a pharmaceutical product by ensuring identity, purity, potency, and strength. These specifications serve as benchmarks during development, manufacturing, and post-approval quality control. Clinically relevant specifications are particularly important because they directly relate to a drug's safety and efficacy in clinical use.Dissolution studies are critical biopharmaceutic tools that link in vitro behavior to in vivo performance. They...
Drug Discovery: Overview01:26

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
Bioequivalence of Drugs: Drugs with Multiple Indications01:09

Bioequivalence of Drugs: Drugs with Multiple Indications

The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each indication due to...
Biopharmaceutical Factors Influencing Drug Product Design: Overview01:22

Biopharmaceutical Factors Influencing Drug Product Design: Overview

Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though pharmacologically...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Automated evaluation can distinguish the good and bad AI responses to patient questions about hospitalization.

NPJ digital medicine·2026
Same author

Quantifying Hallucinations in Language Language Models on Medical Textbooks.

ArXiv·2026
Same author

BioACE: An Automated Framework for Biomedical Answer and Citation Evaluations.

ArXiv·2026
Same author

A Dataset and Resources for Identifying Patient Health Literacy Information from Clinical Notes.

ArXiv·2026
Same author

A Dataset and Benchmark for Consumer Healthcare Question Summarization.

ArXiv·2026
Same author

A Dataset for Addressing Patient's Information Needs related to Clinical Course of Hospitalization.

Scientific data·2026

Related Experiment Video

Updated: May 13, 2026

A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English
14:34

A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English

Published on: April 3, 2026

Extracting drug indication information from structured product labels using natural language processing.

Kin Wah Fung1, Chiang S Jao, Dina Demner-Fushman

  • 1Lister Hill National Center for Biomedical Communications, National Library of Medicine, US National Institutes of Health, Bethesda, MD 20894, USA. kfung@mail.nih.gov

Journal of the American Medical Informatics Association : JAMIA
|March 12, 2013
PubMed
Summary
This summary is machine-generated.

This study demonstrates the feasibility of using natural language processing tools to extract drug indications from drug labels. This method can improve data quality and reduce medication errors in electronic health records.

Related Experiment Videos

Last Updated: May 13, 2026

A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English
14:34

A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English

Published on: April 3, 2026

Area of Science:

  • Biomedical Informatics
  • Natural Language Processing
  • Pharmacovigilance

Background:

  • Drug labels contain crucial indication information but are often in unstructured formats.
  • Electronic health records (EHRs) can benefit from structured drug-indication data to improve patient safety and reduce errors.
  • Automated extraction of drug indications is needed for efficient integration into clinical applications.

Purpose of the Study:

  • To extract drug indications from structured drug labels.
  • To represent extracted drug indications using standard medical terminology codes.
  • To evaluate the feasibility and accuracy of automated extraction methods.

Main Methods:

  • Utilized MetaMap and other public resources for information extraction from drug labels.
  • Encoded drugs and indications using RxNorm and Unified Medical Language System (UMLS) identifiers.
  • Conducted manual review and compared results with National Drug File-Reference Terminology and Semantic Medline.

Main Results:

  • Processed 6797 drug labels, yielding 19,473 unique drug-indication pairs.
  • Achieved a recall of 0.95 and precision of 0.77 in manual physician review.
  • Enhanced precision to 0.93 when results were corroborated by Semantic Medline extractions.

Conclusions:

  • Publicly available natural language processing (NLP) tools can effectively extract drug indications from drug labels.
  • Named entity recognition tools like MetaMap offer reasonable recall for indication extraction.
  • Combining NLP extraction with other data sources significantly improves precision and data utility.